“…The overall survival and progression-free survival of bladder cancer patients with high FOXD2-AS1 expression is shorter than that of bladder cancer patients with low FOXD2-AS1 expression (Su et al, 2018). Overexpressed FOXD2-AS1 is observed in multiple other types of human cancer, including hepatocellular carcinoma (Chang et al, 2018;Zhao et al, 2018;Xu et al, 2019), glioma (Ni et al, 2019), thyroid cancer Jiang et al, 2019;Liu et al, 2019), cutaneous melanoma (Ren et al, 2019), colorectal cancer (Zhu et al, 2018), esophageal squamous cell carcinoma (Bao et al, 2018), and non-small cell lung cancer (Rong et al, 2017). Nevertheless, FOXD2-AS1 expression status in cervical cancer has been unknown and warrants investigation.…”